Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501649-54-01

Acronym

The ‘DREAM’ trial

Enrollment

Registered

2023-02-07

Start date

Unknown

Completion date

2024-04-24

Last updated

2023-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Change in body weight

Detailed description

Body weight reduction ≥ 5%, Body weight reduction ≥ 5%, Change in fasting serum/plasma concentrations of gut permeability biomarkers • LPS, Change in fasting serum/plasma concentrations of inflammation markers. High-sensitivity CRP. Interleukin (IL)-6

Interventions

DRUGPlacebo for dapiglutide

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in body weight	—

Secondary

Measure	Time frame
Body weight reduction ≥ 5%, Body weight reduction ≥ 5%, Change in fasting serum/plasma concentrations of gut permeability biomarkers • LPS, Change in fasting serum/plasma concentrations of inflammation markers. High-sensitivity CRP. Interleukin (IL)-6	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026